SCHEMBL4108486

SCHEMBL4108486

COc1cc(C(C)=O)c([N+](=O)[O-])cc1OC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.59
LMNA P02545 3/20 0.58
HTT P42858 2/20 0.58
POLB P06746 2/20 0.58
MAPT P10636 3/20 0.57
CYP3A4 P08684 2/20 0.56
NPC1 O15118 1/20 0.56
ALDH1A1 P00352 3/20 0.53
KDM4E B2RXH2 2/20 0.53
ALOX15 P16050 1/20 0.53
PRKDC P78527 1/20 0.53
HSD17B10 Q99714 1/20 0.53
CASP3 P42574 1/20 0.52
SENP8 Q96LD8 1/20 0.52
SENP7 Q9BQF6 1/20 0.52
SENP6 Q9GZR1 1/20 0.52
PKM P14618 1/20 0.51
MEN1 O00255 1/20 0.50
GAA P10253 1/20 0.50
KMT2A Q03164 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30716507 1.00 L3MBTL1 (0.59) L3MBTL1LMNAHTTPOLBMAPT
SCHEMBL9908175 0.92 L3MBTL1 (0.53) L3MBTL1LMNAHTTPOLBMAPT
SCHEMBL25362735 0.89 L3MBTL1 (0.51) L3MBTL1LMNAHTTPOLBMAPT
SCHEMBL7521404 0.89 HTT (0.56) L3MBTL1LMNAHTTPOLBMAPT
SCHEMBL19514652 0.88 L3MBTL1 (0.49) L3MBTL1LMNAHTTPOLBMAPT
SCHEMBL9908176 0.88 HTT (0.54) L3MBTL1LMNAHTTPOLBMAPT
SCHEMBL12779095 0.88 L3MBTL1 (0.49) L3MBTL1LMNAHTTPOLBMAPT
SCHEMBL21753420 0.88 POLB (0.52) L3MBTL1LMNAHTTPOLBMAPT
SCHEMBL15275125 0.88 LMNA (0.52) L3MBTL1LMNAHTTPOLBMAPT
SCHEMBL2605630 0.87 LMNA (0.73) L3MBTL1LMNAHTTPOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4703409-A1 LIGHT-RESPONSIVE CELL DESIGNER MOLECULE The University of Osaka (JP) 2026-03-04 EP claimed
WO-2024225384-A1 LIGHT-RESPONSIVE CELL DESIGNER MOLECULE 国立大学法人大阪大学 2024-10-31 WO claimed
CN-102532116-B Synthesis method of anti-tumor targeted therapeutic drug tivozanib WUHAN MAIDESEN MEDICAL TECHNOLOGY CO LTD 2015-01-21 CN claimed
CN-102532116-A Synthesis method of anti-tumor targeted therapeutic drug tivozanib WUHAN MAIDESEN MEDICAL TECHNOLOGY CO LTD 2012-07-04 CN claimed
EP-4703409-A1 LIGHT-RESPONSIVE CELL DESIGNER MOLECULE The University of Osaka (JP) 2026-03-04 EP disclosed
WO-2025133603-A1 LIQUID-PHASE PROCESS FOR PREPARING OLIGONUCLEOTIDES Exactmer Limited (GB) 2025-06-26 WO disclosed
WO-2024225384-A1 LIGHT-RESPONSIVE CELL DESIGNER MOLECULE 国立大学法人大阪大学 2024-10-31 WO disclosed
US-20240201575-A1 PHOTOSENSITIVE SURFACE TREATMENT AGENT, LAMINATE, TRANSISTOR, METHOD FOR FORMING PATTERN AND METHOD FOR MANUFACTURING TRANSISTOR NIKON CORPORATION (JP) 2024-06-20 US disclosed
CN-118146194-A Novel quinoline compound containing 6-oxo-1-substituted phenyl-1, 6-dihydropyridazine-3-carboxamide and application thereof 辽宁大学 2024-06-07 CN disclosed
CN-117813550-A Photosensitive surface treating agent, laminate, transistor, pattern forming method, and method for manufacturing transistor 株式会社尼康 2024-04-02 CN disclosed
CN-117402143-A EGFR inhibitor and preparation and application thereof 上海翰森生物医药科技有限公司 2024-01-16 CN disclosed
CN-117343046-A Novel 3-oxo-4-substituted aryl-3, 4-dihydropyrazine-2-carboxamide compound and application thereof 辽宁大学 2024-01-05 CN disclosed
US-6171756-B1 SOLVENT SOLUBLE ORGANIC PHOTOPRECURSORS OF AMINES FOR USE IN PHOTOSENSITIVE IMAGING SYSTEMS, SAID PHOTOPRECURSORS GENERATING FREE AMINES ON EXPOSURE TO LONG WAVELENGTH UV OR VISIBLE RADIATION, COMPRISING PHOTOLABILE 2-NITROBENZYL GROUPS AFGA-GEVAERT, N.V. (BE) 2001-01-09 US disclosed
US-6017758-A DMNPE caged nucleic acid and vector VANDERBILT UNIVERSITY (US) 2000-01-25 US disclosed
EP-0926555-A1 Photoactive materials applicable to imaging systems. AGFA-GEVAERT N.V. (BE) 1999-06-30 EP disclosed
US-5888829-A Photolabile caged ionophores and method of using in a membrane separation process MOLECULAR PROBES, INC. (US) 1999-03-30 US disclosed
EP-0107398-B1 ORTHO SUBSTITUTED DIHYDROXY-2(1H)QUINAZOLINONE-1-ALKANOIC ACIDS ORTHO PHARMA CORP (US) 1988-06-08 EP disclosed
US-4631283-A RENAL VASODILATORS, CARDIOVASCULAR AGENTS ORTHO PHARMACEUTICAL CORPORATION (US) 1986-12-23 US disclosed
US-4490374-A CARDIOVASCULAR AGENTS ORTHO PHARMACEUTICAL CORPORATION (US) 1984-12-25 US disclosed
EP-0107398-A1 Ortho substituted dihydroxy-2(1H)quinazolinone-1-alkanoic acids ORTHO PHARMACEUTICAL CORPORATION (US) 1984-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240201575-A1 PHOTOSENSITIVE SURFACE TREATMENT AGENT, LAMINATE, TRANSISTOR, METHOD FOR FORMING PATTERN AND METHOD FOR MANUFACTURING TRANSISTOR CDH1, DSG1, KRT18 L3MBTL1 4161/4885LMNA 673/4885HTT 3252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.